Bronchial thermoplasty (BT) provided sustained improvements in patients with severe asthma, according to the results of the BT10+* study presented at ERS 2019.
As-needed budesonide–formoterol (ICS* + LABA**) reliever therapy was more effective than maintenance low-dose budesonide plus as-needed terbutaline (maintenance ICS + as-needed SABA***) for preventing severe exacerbations in patients with mild-to-moderate asthma, according to the PRACTICAL study presented at ERS 2019.
Antibiotic prophylaxis with azithromycin in individuals with primary antibody deficiencies (PAD) may lead to a reduced risk of respiratory exacerbations, according to a phase II trial presented at ERS 2019.
Treatment without antibiotic medication does not appear to be inferior to moxifloxacin therapy as regards treatment failure or length of stay (LOS) among patients with chronic obstructive pulmonary disease (COPD) requiring hospitalization for nonpurulent exacerbation, according to the results of a study presented at the European Respiratory Society (ERS) International Congress 2019.
About one-third of patients with severe asthma who are on high-dose inhaled corticosteroids (ICS) are also receiving excessive doses of oral corticosteroids (OCS), reveals a study presented at the ERS 2019 Meeting.
Use of the Zephyr endobronchial valve (EBV) led to significant improvements in a range of patient-reported outcomes (PROs) including multiple domains of respiratory symptoms and quality of life (QoL) in patients with severe emphysema, according to the post hoc results of the LIBERATE* trial presented at ERS 2019.
Preliminary real-world findings of the REALITI-A* study, presented at ERS 2019, have demonstrated a significant reduction in asthma exacerbations with mepolizumab, a result comparable to that of regulatory clinical trials with this drug.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.